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Resistance to antiepidermal growth factor (EGFR) strategies is an emerging clinical problem. Using human colorectal cancer (CRC)
cells, we evaluated the involvement of the insulin receptor isoform-A (InsR-A) in de novo resistance to gefitinib, an EGFR tyrosine
kinase inhibitor. Challenging the EGFR positive LoVo cells with gefitinib (1mM) resulted in a small (B18%) inhibition of cell growth
and although a modest reduction in phospho (p)EGFR Tyr845 was seen, pEGFR at residues -Tyr1068 and -Tyr1173 were unchanged.
LoVo cells produced unprocessed pro-IGF-1R protein, substantial levels of IGF-II mRNA and mature InsR protein, consisting mainly
of the InsR-A isoform. Insulin and IGF-II promoted cell growth and pEGFR Tyr845, Tyr1068 and Tyr1173 activity and conversely,
the insulin-like growth factor-1 receptor (IGF-1R)/InsR inhibitor ABDP (1mM) inhibited growth and reduced pEGFR activity at all
three tyrosine residues. pInsR and pAkt levels were increased after gefitinib treatment. Blocking of pInsR with ABDP enabled gefitinib
to markedly reduce pEGFR Tyr845, Tyr1068 and Tyr1173. Short-term gefitinib/ABDP dual treatment was more effective than either
agent alone and chronic exposure to this combination resulted in total cell loss after 9 weeks, preventing acquisition of resistance to
ABDP. LoVo cells with acquired resistance to ABDP were acutely sensitive to gefitinib. We concluded that InsR-A reduces sensitivity
to gefitinib in LoVo CRC cells, thus its co-targeting alongside EGFR can improve the anti-tumour effect of gefitinib.
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Colorectal cancer (CRC) is one of the most commonly occurring
human malignancies (Parkin, 2001) and in advanced CRC, the
epidermal growth factor receptor (EGFR) and/or its ligands are
frequently overexpressed and have been implicated in increased
risk of metastasis and hence poor prognosis (reviewed by Spano
et al, 2005) and additionally, increased EGFR expression has also
been associated with chemo-refractory disease (Saltz et al, 2001).
The EGFR therefore, represents a promising therapeutic target in
CRC (Spano et al, 2005). The EGFR is a membrane glycoprotein
consisting of a ligand binding region, a transmembrane segment
and an intracellular portion, the latter containing a tyrosine kinase
domain which is upstream of additional autophosphorylation
tyrosine sites within the carboxy terminus of the receptor (Gullick,
2001). Association of the ligand induces receptor dimerisation and
activates the tyrosine kinase domains of each receptor which
results in the transautophosphorylation of the tyrosine sites on the
other EGFR molecule, activating signalling transduction cascades
which regulate both normal and tumourigenic cellular processes
(Gullick, 2001). Among current strategies for targeting the EGFR
are small molecule inhibitors, including gefitinib (Iressat), which
act by specifically inhibiting the activity of the EGFR tyrosine
kinase (Ciardiello and Tortora, 2001).
Both in vitro and in vivo studies indicated that gefitinib had
antitumour activity as a monotherapy in some (Ciardiello et al,
2000, 2001) but not all CRC cell lines investigated (Williams et al,
2002). Other studies reported that gefitinib could have a synergistic
interaction with chemotherapeutic agents (Ciardiello et al, 2000;
Xu et al, 2003) and radiotherapy in xenograft models for CRC
(Williams et al, 2002). Disappointingly, however, phase I/II clinical
studies in patients with advanced CRC indicated that gefitinib had
negligible single agent activity (Goss et al, 2002; Rothenberg et al,
2004) but the inhibitor was seen to demonstrate modest activity
when used in combination with 5-fluororacil, leucovorin and
irinotecan (Veronese et al, 2005) or FOLFOX-4 (Cho et al, 2005;
Kuo et al, 2005). Additionally, clinical data in other cancer types
has also indicated the existence of de novo and acquired resistance
to gefitinib (Ranson et al, 2002; Schiller, 2002; Kelly and Averbuch,
2004) and interestingly, a clear link between EGFR levels and
predicted response to EGFR-targeted agents including gefitinib has
not been observed (Arteaga, 2002; Ranson et al, 2002; Saltz et al,
2004). Recent evidence has implicated signalling via the type II
receptor tyrosine kinase (RTK) family member the insulin-like
growth factor-1 receptor (IGF-1R) and resistance to various anti-
EGFR therapies (Liu et al, 2001; Chakravarti et al, 2002; Jones et al,
2004). Another member of the type II RTK family however, is the Revised 18 May 2006; accepted 5 June 2006; published online 4 July 2006
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sinsulin receptor (InsR) which shows a high degree of homology
with the IGF-1R (De Meyts and Wittaker, 2002) and has been
reported to play a role in cancer development and progression
(Denley et al, 2003). The InsR occurs in two isoforms which
are produced by the tissue specific alternative splicing of exon 11,
insulin receptor isoform-A (InsR-A) (Ex11 ) and InsR-B (Ex11þ)
(Mosthaf et al, 1990). Both isoforms can bind insulin with high
affinity (Yamaguchi et al, 1993), but InsR-A can also bind
IGF-II with high affinity (Frasca et al, 1999). Furthermore,
stimulation of the InsR-A by insulin and IGF-II can promote
cancer cell mitogenesis and survival (reviewed by Denley et al,
2003). In addition, several clinical cancer types including CRC,
have been shown to preferentially express InsR-A (Frasca et al,
1999; Vella et al, 2002).
In this study, we demonstrate for the first time that LoVo CRC
cells, known to lack functional IGF-1R (Lehmann et al, 1998), not
only express mainly InsR-A vs InsR-B, providing an opportunity to
study InsR-A without molecular manipulation , but furthermore,
the InsR-A can modulate EGFR phosphorylation in the presence
of gefitinib and hence, contribute to the lack of sensitivity to
this inhibitor shown by the EGFR positive LoVo cells. Conse-
quently, we observed that gefitinib sensitivity could be restored
by minimising InsR activity, which translated into a combination
treatment of gefitinib with an IGF-1R/InsR inhibitor being
considerably more efficacious than either inhibitor given as a
single agent. Additionally, gefitinib is extremely effective in
cells which have acquired resistance to the InsR inhibitor, an
observation which may have important ramifications for the
scheduling of agents that target the EGFR. The study clearly
demonstrates the need to elucidate the potential mechanisms
underpinning resistance to anti-EGFR agents such as gefitinib in
order to rationally design combination drug regimes to improve
drug efficacy and maximise antitumour effects. In addition, usually
overshadowed by its more well-known family member, the IGF-1R,
this work also highlights the growing importance of the InsR-A as
a future therapeutic anticancer target.
MATERIALS AND METHODS
Cell culture
LoVo CRC cells (gifted from AstraZeneca Pharmaceuticals,
Macclesfield, Cheshire, UK) were routinely cultured in phenol
red Dulbecco’s modified Eagle’s Medium (DMEM), supplemented
with 10% fetal calf serum (FCS) plus antibiotics. LoVo-ABDP-R
cells were routinely maintained in phenol red DCCM-1 medium
(Biological Industries, Cumbernauld, UK) containing 0.5% FCS
and 1mM ABDP. Both routine and experimental medium was
replaced every 4 days and the cultures were maintained at 371Ci n
a humidified 5% CO2 atmosphere.
Long-term growth studies
Gefitinib and the IGF-1R/InsR tyrosine kinase inhibitor ABDP
were gifts from AstraZeneca. LoVo cells were continuously
exposed to 1mM gefitinib, 1mM ABDP or gefitinib and ABDP in
combination, in phenol red DCCM-1 supplemented with 0.5% FCS.
As gefitinib had little effect on the growth of the LoVo cells, both
control and gefitinib treated cultures were passaged weekly at a
seeding ratio of 1:10. Initially, ABDP alone dramatically reduced
(80%) LoVo cell numbers and during the following 2 months, the
surviving cells were passaged approximately every 2–3 weeks at a
seeding ratio of 1:2. Over the following 2 months the cells were
passaged once every 2 weeks at a seeding ratio of 1:4. A stable
growth rate was reached after a total of 5 months with routine
maintenance of the ABDP-resistant variant (LoVo-ABDP-R)
involving passage every 7 days with a seeding ratio of 1:10 of
the confluent cell number. The gefitinib and ABDP combination
treatment also reduced LoVo cell number and were passaged twice
during 2 months at a seeding ratio of 1:2, however, during the
following month, the cell number declined below the seeding
density and could not be maintained any further.
Cell growth analysis
The LoVo and LoVo-ABDP-R cells were seeded into 24-well plates
in routine cell medium at a density of 6 10
4cellswell
 1. After
24h, the cells were washed with phosphate buffered saline (PBS)
and the experimental treatments were added as detailed below.
LoVo cells were cultured in phenol red DCCM-1 containing (a)
various concentrations of FCS (0–10%) in the absence and
presence of 1mM gefitinib, or (b) EGF, IGF-II (both at 10ngml
 1)
and insulin (10mgml
 1) or (c) various concentrations of the InsR/
IGF-1R inhibitor ABDP (0–10mM) in the absence or presence of
1mM gefitinib with 0.5% FCS. LoVo-ABDP-R cells were challenged
with EGF (10ngml
 1) in the absence and presence of 1mM gefitinib
in phenol red DCCM-1 with 1mM ABDP. Cell population growth
was evaluated after 7 days by Coulter (Luton, UK) counting
analysis. Each experiment was also performed in triplicate.
Western blotting analysis
LoVo and LoVo-ABDP-R cells were seeded into 60mm dishes in
routine medium at a density of 7.5 10
5cellsdish
 1. After 24h,
the experimental treatment regimes were as follows: (a) LoVo
cells were incubated in DCCM-1 with 0.5% FCS for 7 days in
the absence or presence of either 1mM gefitinib or 1mM ABDP or
(b) growth in routine culture medium until 70% confluent, serum
starved in DCCM-1 for 24h and subsequently challenged with
insulin and IGF-II for 5min or EGF, insulin and IGF-II with and
without 1mM ABDP for 5min. Cells exposed to ABDP were
preincubated with this inhibitor for 6h or (c) cells were cultured in
the presence of 1mM ABDP for 4 days before the addition of 1mM
gefitinib. LoVo-ABDP-R cells were grown in the absence and
presence of 1mM gefitinib in phenol red DCCM-1 with 1mM ABDP
for 7 days or challenged with insulin (10mgml
 1) for 5min.
Cell monolayers were harvested and protein samples were
electrophoresed, electroblotted onto nitrocellulose membranes
and blocking solution utilised exactly as described previously
(Jones et al, 2004), before incubation with a variety of antibodies
at 1:1000 dilution unless stated otherwise for 3h at room
temperature. Antibodies used were total EGFR (1:4000) (1005,
Santa Cruz, Biotechnology Inc. CA, USA), pEGFR Tyr845, pEGFR
Tyr1068, total Akt, pAKT Ser473, total ERK1/2, pERK1/2 Thr202/
Tyr204 and pIGF-1R/InsR Tyr1131/1146 (all from Cell Signaling,
Beverly, MA, USA), pEGFR Tyr1173 (Upstate Biotechnology UK,
Buckingham, UK) and total IGF-1R (N-20) and InsR (N-20) (both
from Santa Cruz). The membranes were further incubated with
the appropriate secondary IgG horse radish peroxidase labelled
antibody and proteins were visualised by chemiluminescence. The
resulting bands were analysed by scanning densitometry and
normalised to b-actin.
RT–PCR
RNA was harvested from the cells using an RNA Isolator kit
(Sigma Chemical Co., Dorset, UK) according to the manufacturer’s
instructions. Total RNA (1mg) was reverse transcribed and the
resulting cDNA was amplified using specific primer sets for TGF-a
(50 CCACACTCAGTTCTGCTTCC and 30 TCTTTATTGATCTGCC
ACAGTC), insulin (50 TCACACCTGGTGGAAGCTC and 30 ACAAT
GCCACGCTTCTGC) and IGF-II (50 TGGGAATCCCAATGGGG
AAG and 30 CTTGCCCACGGGGTATCT). Pancreatic cDNA (BD
Biosciences, Erembodegem, Belgium) was utilised as a control for
insulin. In parallel, b-actin c-DNA (50 GGAGCAATGATCTTGAT
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sCTT and 30 CCTTCCTGGGCATGGAGTCCT) was amplified in
replicate samples as an internal control. PCR amplification
consisted of 1min at 941C, 30s at 551C and 1min at 721C for 30,
35 and 27 cycles for TGF-a, insulin, IGF-II and b-actin,
respectively. The resulting amplified c-DNA fragments were
resolved on agarose gels stained with ethidium bromide, analysed
by scanning densitometry and normalised relative to b-actin. InsR
isoform detection was determined using primers as described by
Sciacca et al (1999), which spanned nucleotides 2229–2250 (50 AA
CCAGAGTGAGTATGAGGAT 30) and 2844–2865 (50 CCGTTCCAG
AGCGAAGTGCTT 30) of the human insulin receptor. PCR
amplification was carried out for 35 cycles using the conditions
detailed above. The PCR products were resolved on 15%
polyacrylamide gels and fragments of 600 and 636bp representing
InsR-A Ex 11 and InsR-B Exþ11 were detected by ethidium
bromide staining, scanned and normalised to b-actin as described
previously. In order to verify that the larger cDNA fragment was
InsR-B, the RT–PCR products were subjected to digestion with
the restriction enzyme BanI. Only cDNA containing exon 11, the
restriction site for BanI, was digested, leaving InsR-A Ex-11 intact.
Statistical analysis
Overall differences between control and treatment groups were
examined by means of a Kruskall–Wallis test. Direct comparisons
between control and treatment effects were assessed using a two-
sided Mann–Whitney test. Significance was determined at the
Po0.05 level.
RESULTS
Effect of gefitinib on cell growth and EGFR
phosphorylation status
When compared to the matching control, LoVo cells grown in
medium containing 10% serum, showed a growth inhibition of
16.1% (CI¼7.9–24.3, P¼0.03) when challenged with 1mM
gefitinib (Figure 1A). Cells grown in medium containing 7.5, 5,
2.5 1, 0.5 and 0% serum showed 25.7, 16.9, 8.9, 16.4, 18.1 and 27.6%
growth inhibition to gefitinib, respectively, and in comparison
with the growth inhibition determined in the presence of 10%
serum, it was noted that reducing the serum content did not
reveal a further significant growth response to the inhibitor (with
P-values being 0.768 or greater) (Figure 1A).
It should be noted that throughout the study, following
densitometric analysis and normalisation of the Western blot
data, control values were taken to represent 100% and an average
increase or decrease greater than 20% after experimental treatment
from triplicate samples was considered to represent changes in
expression or activity of the protein of interest.
The LoVo cells expressed considerable basal amounts of EGFR
protein, which was phosphorylated (Figure 1B). The effect of
gefitinib on the phosphorylation of specific tyrosine residues
within the EGFR demonstrated that compared with the controls,
the gefitinib-treated LoVo cells consistently showed a reduction
in pEGFR Tyr845 activity, the tyrosine site located in the
kinase domain of the receptor, whereas the levels of activity of
the downstream autophosphorylation sites pEGFR Tyr1068 and
pEGFR Tyr1173, however, appeared unaltered (Figure 1B). Simi-
larly, gefitinib was without any apparent inhibitory effect on the
activity of pERK1/2 (Figure 1B). In order to confirm that the EGFR
signalling pathway was intact in these cells, it was established that
challenge with EGF produced marked increases in the activity of
pEGFR Tyr1068/1173 which was accompanied by increases in
the activity of the downstream signalling targets Akt and ERK1/2
whereas the expression of EGFR, Akt and ERK1/2 remained
unchanged (Figure 1C). It was also shown by RT–PCR studies that
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Figure 1 Response to gefitinib and basal EGFR expression and
phosphorylation status. (A) LoVo cells were grown in DCCM-1 containing
varying serum concentrations (0–10%) in the absence and presence of
1mM gefitinib. Data are mean values of three independent experiments
(every point in each individual experiment also being evaluated in triplicate)
and error bars represent 95% CIs. Significant differences were assessed at
the Po0.05 level between the growth inhibition value obtained in the
presence of 10% serum and gefitinib and the growth inhibitory values seen
with each of the other serum concentrations in the presence of gefitinib.
(B) Cells were grown in DCCM-1 with 0.5% serum in the absence and
presence of 1mM gefitinib for 7 days. Protein (75mg) of cell lysate was
electrophoresed by SDS–PAGE (7.5%) and immunoblotted for total
EGFR, phospho (p)-EGFR Tyr845, pEGFR Tyr1068, pEGFR Tyr1173 and
pERK1/2. Densitometric analysis was performed and results were normal-
ised to b-actin levels. The data illustrated are representative of three
separate experiments. (C) After growing to 70% confluency and serum
starvation for 24h, cells were challenged with EGF (5min). Samples were
electrophoresed and immunoblotted for total EGFR, pEGFR Tyr1068,
pEGFR Tyr1173, total Akt, pAkt, total ERK1/2 and pERK1/2 and analysed as
detailed in (B). (D) Cells were harvested for RNA, RT–PCR was
performed and the resulting cDNA was amplified using primer sets for
TGF-a. Fragments were resolved on agarose gels and densitometric scores
were normalised to b-actin. Data represents mean values of three
experiments and error bars indicating 95% CIs.
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sthe LoVo cells produced considerable levels of the EGFR ligand
TGF-a in comparison to A549 and DU145 cells (Figure 1D).
Expression of components of the IGF-1R and InsR
signalling pathway
LoVo cells expressed high levels of uncleaved pro-IGF-1R protein,
represented by the band seen at B200kDa and no mature receptor
at 130kDa, in contrast to A549 (non-small-cell lung carcinoma),
DU145 (prostate) and MCF-7 (breast) cancer cell lines (Figure 2A).
The LoVo cells, however, produced mature InsR protein as
determined by the presence of a band at 125kDa (Figure 2A),
whereas immature InsR at B200kD was not detected in any of the
cell lines evaluated. RT–PCR studies subsequently indicated that
compared with the A549, DU145 and MCF-7 cells, the LoVo cells
produced significantly higher (3.6–45-fold, Po0.001) levels of
IGF-II mRNA (Figure 2B). Insulin mRNA was not detected in any
of the cell lines.
The presence of the A and B isoforms of the InsR was assessed
and RT–PCR studies showed the existence of 600 and 636bp
fragments, representing Ins-A (Ex11 ) and Ins-B (Ex11þ),
respectively, and also indicated that in comparison with the
A549, DU145 and MCF-7 cancer cells, LoVo cells consistently
expressed elevated amounts of InsR-A mRNA, with minimal
detection of InsR-B mRNA (Figure 2C). As exon 11 contains the
restriction site for BanI restriction enzyme, the presence of InsR-A
(Ex11 ) was confirmed by its resistance to degradation by the
enzyme. For example, in the DU145 cells, only InsR-B containing
Exon 11 is digested by Ban1, whereas the InsR-A in both LoVo and
DU145 cells remained intact (Figure 2D).
Western blotting analysis further showed that the LoVo cells
contained phosphorylated InsR which moreover, demonstrated a
consistent increase in activity after challenge with gefitinib. InsR
expression appeared to be unaltered after exposure to gefitinib
(Figure 2E). In addition both the expression and activity of Akt, a
common downstream target for InsR signalling, was elevated in all
samples studied following exposure to gefitinib (Figure 2E).
Effect of growth factors and the InsR/IGF-1R inhibitor
ABDP on cell proliferation
The potential importance of type II RTK signalling in mediating
LoVo cell growth was demonstrated by the observation that small
significant increases in growth were promoted by IGF-II (mean
24%, CI¼13–35, P¼0.025) and insulin (mean 55%, CI¼34–76,
P¼0.009) compared with control values (Figure 3A). In contrast,
EGF was without significant effect (mean 98%, CI¼91–104,
P¼0.999).
Challenge of the cells with the InsR/IGF-1R inhibitor ABDP,
revealed a role for InsR in the basal growth of the cells, where it
resulted in significant (Po0.001) dose-dependent decreases in
LoVo cell number (IC50¼0.4mM) for example at 1mM ABDP,
mean decrease 90.4%, CI¼88.4–92.4, Po0.001 (Figure 3B). ABDP
inhibits both IGF-1R and InsR tyrosine kinase activity, with
increased selectivity for the IGF-1R. Given the observation that
the InsR is the predominant mature type II RTK in LoVo cells,
however, it is likely that any effects seen as a result of exposure to
the inhibitor are exerted through the InsR.
Modulation of InsR-A and EGFR phosphorylation by
insulin, IGF and ABDP
Marked increases in pInsR were seen after challenge with insulin
and IGF-II, while total InsR expression remained constant.
(Figure 4A). This was complimented by consistent increases in
pEGFR Tyr845, pEGFR Tyr1068 and pEGFR Tyr1173 following a
5min stimulation with insulin and IGF-II while total EGFR
expression appeared unaltered (Figure 4A). The effect of ABDP
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Figure 2 Evaluation of IGF-1R and InsR signalling pathway components.
LoVo, A549, DU145 and MCF-7 cells were grown in DCCM-1 with 0.5%
serum for 7 days. (A) Protein (75mg) of cell lysate was electrophoresed by
SDS–PAGE (7.5%) and immunoblotted for total IGF-1R and InsR. (B) Cells
were harvested for RNA, RT–PCR was performed and the resulting
cDNA was amplified using primer sets for IGF-II. Fragments were resolved
on agarose gels and densitometric scores were normalised to b-actin. Data
represents mean values of three experiments and error bars indicating 95%
CIs. *Shows significant differences assessed between LoVo cells and each of
the other cell lines at the Po0.05 level. (C) Amplified InsR-A and InsR-B
cDNA was resolved by PAGE (15%) and normalised to b-actin. (D)
Following PCR amplification for InsR-A and InsR-B, the PCR products were
digested with Ban I restriction enzyme, before resolution by PAGE. Data
illustrates nondigested (ND) and digested (D) cDNA fragments in LoVo
and DU145 samples. (E) Cells were grown in DCCM-1 with 0.5% serum in
the absence and presence of 1mM gefitinib for 7 days. Protein (75mg) of cell
lysate was electrophoresed by SDS–PAGE (7.5%) and immunoblotted for
total and phosphorylated InsR and Akt.
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son EGFR phosphorylation indicated that in the presence of this
inhibitor pEGFR Tyr 845, pEGFR Tyr1068 and pEGFR Tyr 1173
were all consistently reduced (Figure 4B).
The effectiveness and specificity of ABDP was confirmed as the
inhibitor prevented the strong stimulation of InsR phosphoryla-
tion by insulin, however, EGF-induced phosphorylation of the
EGFR at multiple tyrosine sites was unaffected by the inhibitor.
The expression of both total InsR and EGFR appeared unaltered by
the treatments (Figure 4C). Furthermore, it was observed that
ABDP could prevent IGF-II and insulin-induced growth promotion
in the LoVo cells, but as these cells do not respond to EGF, the
specificity of ABDP could not be definitively demonstrated by
anchorage-dependent growth assays (data not shown).
Combination studies using gefitinib and ABDP
The effect of gefitinib and ABDP in combination on cell
proliferation vs ABDP alone was evaluated. It was demonstrated
that the combination treatment produced small but significant
additive effects on the inhibition of cell growth compared with
ABDP as a single agent after short-term (7 days) challenge, that is,
mean decrease 17.2%, CI¼12.2–22.2, Po0.001 at 0.1mM ABDP,
mean decrease 10.2%, CI¼7.2–13.2, Po0.001 at 0.25mM ABDP
and mean decrease 18%, CI¼11–25, Po0.001 at 0.5mM ABDP
(Figure 5A). Western blotting studies subsequently showed that
when InsR activity was minimised, sensitivity to gefitinib was
restored as following a period of prior incubation with ABDP,
subsequent challenge with gefitinib resulted in a consistent
reduction in pEGFR Tyr845, Tyr1068 and Tyr1173, which was
complemented by a fall in both ERK1/2 and Akt activation
(Figure 5B). These observations were in complete contrast to the
data obtained when LoVo cells were challenged with gefitinib as a
single agent, and such control samples were also undertaken
within these experimental samples and the results were as already
presented in Figures 1B and 2E, which shows that gefitinib has no
effect on EGFR/ERK1/2 activity and increases Akt activity. Equally
it was confirmed that ABDP reduced EGFR activity exactly as
already shown in Figure 4B. The minimising of InsR signalling was
demonstrated by the inability of insulin to stimulate InsR
phosphorylation in the ABDP containing samples (data not shown
but similar to that illustrated in Figure 4C). Importantly, the small
additive effect on growth inhibition of the ABDP/gefitinib
combination seen over the short-term in Figure 5A, however,
translated out into total cell loss over chronic exposure after
approximately 9 weeks. Moreover, LoVo cells continually treated
with ABDP alone, although initially growth inhibited, eventually
developed resistance and the stable resistant subline (LoVo-ABDP-
R) was established by 20 weeks (Figure 5C). No difference was
noted between control cell growth and gefitinib-treated cells over
long-term challenge (Figure 5C).
Characterisation of LoVo-ABDP-R cell line
The effect of EGF and gefitinib the growth of the LoVo-ABDP-R
cell line was determined. Significant increases in growth were
promoted by EGF (mean 72%, CI¼65–79, Po0.001) compared
with control values (Figure 6A). Gefitinib treatment resulted in a
dramatic reduction (mean 79%, CI¼75–83, Po0.001) in basal
cell growth and prevented EGF-induced growth (mean 69%,
CI¼67–71, Po0.001) (Figure 6A). Although ABDP reduced the
considerable basal pEGFR Tyr845, Tyr1068 and Tyr1173 activity in
the LoVo cells (Figure 4B), interestingly, the LoVo-ABDP-R
cells showed similar basal levels of EGFR phosphorylation to
their untreated parents indicating a substantial recovery of EGFR
activity (Figure 6B) which moreover, could be consistently
effectively reduced by gefitinib (Figure 6B). This was accompanied
by a concomitant fall in the activity of both ERK1/2 and Akt
(Figure 6B). Hence acquisition of resistance to ABDP has
created a response to gefitinib (Figure 6B). In addition, compared
to the parental LoVo cell line, the ABDP-resistant variant
demonstrated similar levels of expression of InsR, which showed
minimal stimulation after challenge with insulin or IGF-II (data
not shown).
DISCUSSION
Drug resistance, either de novo or acquired after initial response,
to molecular-targeted anticancer drugs such as gefitinib is an
emerging clinical problem (Vidal et al, 2004) as we seek to fulfil
their therapeutic potential. Indeed, LoVo CRC cells have abundant
EGFR expression and activity, yet show only modest sensitivity to
gefitinib as a single agent, despite the inhibitor being used at a
concentration previously shown to be highly efficacious in other
EGFR-positive cell lines (Jones et al, 2004). We have previously
shown that increased IGF-1R signalling plays a key role in the
development of acquired resistance to gefitinib in breast and
prostate cancer cells (Jones et al, 2004) and we have postulated
that such signalling, if present at high levels in cancer cells, may
be responsible for de novo resistance to EGFR blockade.
Interestingly, however, although the LoVo cells were able to
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Figure 3 Growth responses of LoVo cells to mitogenic growth factors
and the InsR/IGF-1R inhibitor ABDP. (A) LoVo cells were challenged with
EGF, IGF-II (both at 10ngml
 1) and insulin (10mgml
 1) for 7 days in
DCCM-1 serum-free medium. Data are mean values of three independent
experiments (every point in each individual experiment also being
evaluated in triplicate) and error bars represent 95% CIs. *Significant
differences were assessed at the Po0.05 level. (B) LoVo cells were grown
in the absence and presence of varying concentrations of ABDP (0–5mM)
in DCCM-1 with 0.5% serum for 7 days. Data are mean values of three
independent experiments (every point in each individual experiment also
being evaluated in triplicate) and error bars represent 95% CIs. *Significant
differences were assessed at the Po0.05 level.
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sproduce pro-IGF-1R, they were unable to process it to a mature
phosphorylated species and this receptor therefore, is unlikely to
play a role in the de novo gefitinib resistance seen in these cells.
This conclusion is further supported by studies from other
workers which demonstrated that in LoVo cells, this pro-IGF-1R
cannot transduce intracellular signals (Lehmann et al, 1998). The
inability of the LoVo cells to produce mature IGF-1R is consistent
with their deficiency in the proprotein convertase furin, which is
required to generate the mature or active forms of numerous latent
proteins including the IGF-1R (Lehmann et al, 1998) and the InsR
(Robertson et al, 1993). Surprisingly, however, mature phosphory-
lated InsR was present in the cells suggesting that the InsR was
processed via an alternative furin-independent pathway. It has
been shown, for example, that although cleavage by furin is
regarded as a key event in the activation of membrane type-1
metalloproteinase (MT1-MMP), in furin-devoid LoVo cells, MT1-
MMP could rapidly be converted into its activated form via an
alternative route (Deryugina et al, 2004). Interestingly, RT-PCR
analysis showed that the LoVo cells preferentially expressed InsR-
A isoform as opposed to InsR-B and also produced substantial
levels of IGF-II mRNA, a known ligand for InsR-A (Frasca et al,
1999; Sciacca et al, 1999). This suggests that the activity of the
InsR-A may be promoted in an autocrine fashion, a concept
confirmed by our findings that not only insulin but also IGF-II,
significantly induced cell proliferation and conversely, substantial
growth inhibition was seen after challenge with the IGF-1R/InsR
inhibitor ABDP. Indeed, differential expression of the InsR-A by
cancer cells compared to their normal counterparts has been
reported in colon, lung, breast (Frasca et al, 1999) and thyroid
cancer clinical samples (Vella et al, 2002) and additionally, these
cancer types frequently overexpress IGF-II (Quinn et al, 1996;
Renehan et al, 2000). In addition, other studies have shown that
whereas IGF-II mainly induces mitogenesis after activating the
InsR-A, insulin can also promote cell proliferation after binding to
the InsR-A, as well as being able to drive metabolic events via this
InsR isoform (Frasca et al, 1999).
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Figure 4 Modulation of pEGFR activity by insulin and IGF-II and the InsR/IGF-1R inhibitor ABDP. (A) LoVo cells were grown in routine culture medium
until 70% confluent and after 24h in serum-free DCCM-1 were challenged with IGF-II (10ngml
 1) and insulin (10mgml
 1) for 5min. Cell lysates (75mg)
were electrophoresed by SDS–PAGE (7.5%) and immunoblotted for total InsR, pInsR Tyr1146, total EGFR, pEGFR Tyr845, pEGFR Tyr1068, pEGFR
Tyr1173. Densitometric analysis was performed and results were normalised to b-actin levels. The data illustrated are representative of three separate
experiments. (B) LoVo cells were grown in the absence and presence of 1mM ABDP in DCCM-1 with 0.5% serum for 7 days and electrophoresed,
immunoblotted for pEGFR Tyr845, pEGFR Tyr1068, pEGFR Tyr1173 and analysed as described in (A). (C) LoVo cells were grown in routine culture
medium until 70% confluent and after 24h in DCCM-1, were challenged with insulin (10mgml
 1) and EGF (10ngml
 1) with and without 1mM ABDP for
5min. Cells exposed to ABDP were preincubated with this inhibitor for 6h before electrophoresis, immunoblotting for total InsR, pInsR Tyr1146, pEGFR
Tyr845, pEGFR Tyr1068, pEGFR Tyr1173 and analysis as described in (A).
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sSignificantly, exposure of the LoVo cells to insulin and IGF-II,
not only promoted the activation of InsR-A signalling but also
increased EGFR phosphorylation at residues Tyr845, Tyr1068
and Tyr1173, whose activation moreover, could be substantially
reduced after exposure to the InsR/IGF-1R inhibitor ABDP. In
comparison, gefitinib had no effect on pEGFR Tyr1068 and
Tyr1173 and only a partial inhibitory effect on pEGFR Tyr845
activity. This lack of effect of gefitinib on EGFR activity was not
due to receptor dysfunction as EGF challenge substantially
increased EGFR activity, together with Akt and ERK1/2 activity
indicating that the EGFR signalling pathway was intact. On the
basis of all these data, we hypothesised that the lack of growth
inhibitory effects of gefitinib in LoVo cells was due to the
activation of the EGFR by InsR-A signalling, Furthermore, since
gefitinib treatment also increased InsR-A signalling and down-
stream Akt activity, it is possible that gefitinib acts to limit its own
efficacy, essentially aiding the promotion of the transactivation of
the EGFR by the InsR-A. It is established that modulation of EGFR
activity can occur by several routes including crosstalk or
transactivation by other erbB family members (Gullick, 2001)
but critically, by other heterologous growth factor receptors such
as the IGF-1R (reviewed by Adams et al, 2004) and we have shown
that the InsR-A, which shares a high degree of structural homology
with the IGF-1R (De Meyts and Wittaker, 2002), may also engage
in crosstalk with the EGFR. We have previously demonstrated that
in our tamoxifen resistant breast cancer cells, the IGF-1R can
modulate pEGFR Tyr845 activity via mechanism dependent upon
the non receptor tyrosine kinase c-Src (Knowlden et al, 2004) and
furthermore, other studies have shown that in colon cancer cell
lines with high IGF-1R expression, the IGF-1R can activate c-Src to
modify cell transformation and motility (Sekharam et al, 2003).
Consequently, the role of c-Src as a potential intermediate between
the InsR and EGFR is being evaluated in the LoVo cells.
From these current results, we would predict that blockade
of InsR-A signalling might improve the efficacy of gefitinib and
indeed, our studies showed that a combinatorial strategy of
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Figure 5 Gefitinib and ABDP in combination are more effective than
either agent alone. (A) LoVo cells were cultured in varying concentrations
of ABDP (0–1mM) in the absence (filled bar) or presence (spotted bar) of
1mM gefitinib in DCCM-1 with 0.5% serum for 7 days. Data are mean
values of three independent experiments (every point in each individual
experiment also being evaluated in triplicate) and error bars represent 95%
CIs. *Significant differences were assessed at the Po0.05 level. (B) LoVo
cells were grown in DCCM-1 with 0.5% serum containing 1mM ABDP for 4
days and subsequently challenged with ABDP and gefitinib in combination
for 24h. Cell lysate (75mg) was electrophoresed by SDS–PAGE (7.5%)
and immunoblotted for total EGFR, pEGFR Tyr845, pEGFR Tyr1068,
pEGFR Tyr1173, pAkt and pERK1/2. Data was assessed by densitometry
and are representative of three separate experiments. (C) LoVo cells were
chronically exposed to control media i.e. DCCM-1 with 0.5% serum (-~-),
1mM gefitinib (
y&
y), 1mM ABDP (-m-) or gefitinib/ABDP dual treatment
(-K-) until cell loss occurred or resistance developed. The data
demonstrates the total passage number with respect to time (weeks).
0
40
80
120
160
200
Con EGF Gef EGF/Gef
C
e
l
l
 
g
r
o
w
t
h
 
(
%
 
o
f
 
c
o
n
t
r
o
l
) *
* *
Total ERK1/2
LoVo- LoVo-
ABDP-R ABDP-R
+
LoVo LoVo
pAkt
pERK1/2
Total Akt
+
Total EGFR
pEGFR Tyr845
pEGFR Tyr1068
pEGFR Tyr1173
-Actin
A
B
Figure 6 LoVo-ABDP-R cells have gained sensitivity to gefitinib. (A)
LoVo-ABDP-R cells were challenged with EGF (10ngml
 1), gefitinib (1mM)
and EGF/gefitinib together for 7 days in DCCM-1 serum-free medium
containing 1mM ABDP. Data are mean values of three independent
experiments (every point in each individual experiment also being
evaluated in triplicate) and error bars represent 95% CIs. *Significant
differences were assessed at the Po0.05 level. (B) LoVo cells were grown
in DCCM-1 with 0.5% serum for 7 days and LoVo-ABDP-R cells were
cultured in the absence and presence of 1mM gefitinib for 7 days in DCCM-
1 supplemented with 0.5% serum and 1mM ABDP for 7 days. Protein
(75mg) of cell lysate was electrophoresed by SDS–PAGE (7.5%) and
immunoblotted for total EGFR, pEGFR Tyr845, pEGFR Tyr1068, pEGFR
Tyr1173, total ERK1/2, pERK1/2, total Akt and pAkt. Densitometric analysis
was performed and results were normalised to total expression levels. The
data illustrated are representative of three separate experiments.
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InsR-A, respectively, demonstrated that over 7 days, a small but
significant additive effect on growth inhibition with the dual
treatment was seen compared with ABDP alone. Excitingly,
however, chronic exposure to ABDP revealed that while the cells
were able to overcome its effectiveness and develop resistance to
this inhibitor, the apparent initial small effect of the gefitinib/
ABDP combination translated out into a substantial increase in cell
loss preventing the development of acquired resistance to ABDP.
Signalling analysis showed that whereas alone, gefitinib had no
effect on the activity of the EGFR, under conditions where InsR-A
signalling was blocked, gefitinib effects were restored as the
inhibitor could reduce pEGFR at the multiple tyrosine residues and
subsequently a decrease in ERK1/2 and Akt activation was also
noted. Interestingly, other workers have shown that the anti-
HER-2 agent traztuzumab could only inhibit the growth of MCF-7/
HER-18 cells, which over-express HER-2 receptors and express
IGF-1R, when IGF-1R signalling was minimised (Lu et al, 2001).
Critically our results show that gefitinib, although having little
effect on LoVo cell growth as a monotherapy, is a crucial
component in a combination strategy that additionally targets
the InsR, as a dynamic interplay exists between the EGFR and the
InsR. Such observations are further exemplified by our findings
that the LoVo cells which have gained acquired resistance to the
InsR inhibitor ABDP, show a reliance on EGFR signalling as
demonstrated by their growth promotion by EGF, recovered levels
of EGFR phosphorylation compared with their ABDP-treated
parents and extreme sensitivity to growth inhibition by gefitinib
exerted via a fall in EGFR activity, each observation being in
complete contrast to those shown by the parental cells.
In summary, the conceptual ideal where drugs specifically target
elements involved in cancer, providing greater activity and
specificity than is currently offered by traditional chemotherapeu-
tic agents has proved to have some obstacles. Function redun-
dancy, signalling via alternative signalling pathways or growth
factor receptor crosstalk has shown that the antitumour activity of
monotherapeutic regimes are easily subverted. Our results have
extended our previous observations of the importance of type II
RTKs in gefitinib resistance and support the rationale of
combination strategies that target the InsR-A or IGF-1R in concert
with the EGFR for maximum antitumour effects. It is also
noteworthy that the capability of the InsR-A to crosstalk with
the EGFR has important implications for the use of highly specific
IGF-1R inhibitors which are currently being developed and
evaluated (Hofmann and Garcia-Echeverria, 2005) and may be
used as a monotherapy or in cotargeting strategies with EGFR
inhibitors, as in this scenario, the resulting uninhibited InsR-A
could conceivably substitute for the IGF-1R providing a potential
resistance mechanism to IGF-1R inhibition.
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